• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Kiper Christopher S

    6/5/23 4:17:24 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LNDC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Kiper Christopher S

    (Last) (First) (Middle)
    12121 WILSHIRE BLVD, SUITE 1240

    (Street)
    LOS ANGELES CA 90025

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    LIFECORE BIOMEDICAL, INC. \DE\ [ LFCR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/01/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Rule 10b5-1(c) Transaction Indication

      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock(1) 06/01/2023 A(4) 18,182(4) A (2)(3) 28,069(4) D(4)(5)
    Common Stock(1) 2,772,956 I By: Legion Partners, L.P. I(6)
    Common Stock(1) 167,184 I By: Legion Partners, L.P. II(7)
    Common Stock(1) 200 I By: Legion Partners Holdings, LLC(8)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    Kiper Christopher S

    (Last) (First) (Middle)
    12121 WILSHIRE BLVD, SUITE 1240

    (Street)
    LOS ANGELES CA 90025

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Legion Partners Asset Management, LLC

    (Last) (First) (Middle)
    12121 WILSHIRE BLVD., SUITE 1240

    (Street)
    LOS ANGELES CA 90025

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Legion Partners, L.P. I

    (Last) (First) (Middle)
    12121 WILSHIRE BLVD.
    SUITE 1240

    (Street)
    LOS ANGELES CA 90025

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Legion Partners, L.P. II

    (Last) (First) (Middle)
    12121 WILSHIRE BLVD.
    SUITE 1240

    (Street)
    LOS ANGELES CA 90025

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Legion Partners, LLC

    (Last) (First) (Middle)
    12121 WILSHIRE BLVD., SUITE 1240

    (Street)
    LOS ANGELES CA 90025

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Legion Partners Holdings, LLC

    (Last) (First) (Middle)
    12121 WILSHIRE BLVD., SUITE 1240

    (Street)
    LOS ANGELES CA 90025

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    White Raymond T.

    (Last) (First) (Middle)
    12121 WILSHIRE BLVD.
    SUITE 1240

    (Street)
    LOS ANGELES CA 90025

    (City) (State) (Zip)
    Explanation of Responses:
    1. This Form 4 is filed jointly by Legion Partners, L.P. I, Legion Partners, L.P. II, Legion Partners, LLC, Legion Partners Asset Management, LLC ("Legion Partners Asset Management"), Legion Partners Holdings, LLC, Christopher S. Kiper and Raymond White (collectively, the "Reporting Persons"). Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
    2. The restricted stock units convert into common stock of Lifecore Biomedical, Inc. (the "Issuer") on a 1 for 1 basis.
    3. The restricted stock units will vest and be settled on the earlier of the 1st anniversary of the grant date or the date of the 2024 Annual Meeting of Stockholders (provided such date is no less than 50 weeks from grant date).
    4. Mr. Kiper serves on the Board of the Issuer as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control.
    5. The securities described in footnotes (2) and (3) represent securities in which Legion Partners Asset Management has all of the direct economic interest. Legion Partners Holdings is the sole member of Legion Partners Asset Management and each of Messrs. Kiper and White are Managing Directors of Legion Partners Asset Management. As a result of these relationships, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners Asset Management.
    6. Securities owned directly by Legion Partners I. General Partner is the general partner of Legion Partners I, Legion Partners Asset Management is the investment advisor of Legion Partners I, Legion Partners Holdings is the sole member of Legion Partners Asset Management and managing member of General Partner, and each of Messrs. Kiper and White are managing directors of Legion Partners Asset Management and managing members of Legion Partners Holdings. As a result of these relationships, General Partner, Legion Partners Asset Management, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners I.
    7. Securities owned directly by Legion Partners II. General Partner is the general partner of Legion Partners II, Legion Partners Asset Management is the investment advisor of Legion Partners II, Legion Partners Holdings is the sole member of Legion Partners Asset Management and managing member of General Partner, and each of Messrs. Kiper and White are managing directors of Legion Partners Asset Management and managing members of Legion Partners Holdings. As a result of these relationships, General Partner, Legion Partners Asset Management, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners II.
    8. Securities owned directly by Legion Partners Holdings. As managing members of Legion Partners Holdings, Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners Holdings.
    Remarks:
    Christopher S. Kiper, a Managing Director of Legion Partners Asset Management, is a director of the Issuer. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of the Reporting Persons (other than Mr. Kiper) may be deemed a director by deputization by virtue of Mr. Kiper's representation on the Board of the Issuer.
    /s/ Christopher S. Kiper 06/05/2023
    Legion Partners Asset Management, LLC, By: /s/ Christopher S. Kiper, Managing Member 06/05/2023
    Legion Partners, L.P. I, By: Legion Partners Asset Management, LLC, By: /s/ Christopher S. Kiper, Managing Member 06/05/2023
    Legion Partners, L.P. II, By: Legion Partners Asset Management, LLC, By: /s/ Christopher S. Kiper, Managing Member 06/05/2023
    Legion Partners, LLC, By: Legion Partners Holdings, LLC, By: /s/ Christopher S. Kiper, Managing Member 06/05/2023
    Legion Partners Holdings, LLC, By: /s/ Christopher S. Kiper, Managing Member 06/05/2023
    /s/ Raymond White 06/05/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LNDC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LNDC

    DatePrice TargetRatingAnalyst
    8/11/2022$14.00Mkt Perform → Outperform
    Barrington Research
    7/20/2022$13.00Overweight
    Stephens
    4/6/2022Outperform → Mkt Perform
    Barrington Research
    10/4/2021$15.00 → $14.00Buy
    Roth Capital
    7/30/2021$12.00 → $15.00Buy
    Roth Capital
    More analyst ratings

    $LNDC
    SEC Filings

    View All

    Landec Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

    2/16/24 4:12:45 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Landec Corporation

    SCHEDULE 13G - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

    2/14/24 3:39:52 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Landec Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

    1/12/24 4:51:33 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Landec upgraded by Barrington Research with a new price target

    Barrington Research upgraded Landec from Mkt Perform to Outperform and set a new price target of $14.00

    8/11/22 9:23:39 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stephens initiated coverage on Landec with a new price target

    Stephens initiated coverage of Landec with a rating of Overweight and set a new price target of $13.00

    7/20/22 7:31:01 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Landec downgraded by Barrington Research

    Barrington Research downgraded Landec from Outperform to Mkt Perform

    4/6/22 9:22:55 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lifecore Biomedical Announces Completion of Corporate Name Change

    Common stock expected to begin trading tomorrow under new Nasdaq ticker symbol "LFCR" Lifecore global headquarters relocated to Chaska, MN Launches new investor relations website: ir.lifecore.com CHASKA, Minn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has completed its transition to Lifecore Biomedical, including the change of its name from Landec Corporation to Lifecore Biomedical, Inc. In connection with this change, the Company's common stock is also expected to commence trading under its new Nasdaq ticker symbol "LFCR" tomorrow, N

    11/14/22 9:01:56 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifecore Biomedical to Participate in the Stephens Annual Investment Conference on Thursday, November 17, 2022

    CHASKA, Minn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Lifecore" or the "Company"), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. ("Lifecore") and Curation Foods, Inc. ("Curation Foods"), – today announced that Jim Hall, CEO of Landec Corporation & President of Lifecore, and John Morberg, CFO will be hosting a fireside chat at the Stephens Annual Investment Conference in Nashville, TN. The Company will participate in a fireside chat on Thursday, November 17th at 8:00 AM CT. The live audio webcast will be available to all interested parties through a live audio webcast accessible on the Company's investor rel

    11/10/22 8:00:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Landec Expects to Change Corporate Name to Lifecore Biomedical and Ticker Symbol to "LFCR" on November 14

    CHASKA, Minn., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Lifecore" or the "Company") today announced that it expects to effect its previously announced corporate name change to Lifecore Biomedical, Inc. and to cause its common stock to begin trading on Nasdaq under the ticker symbol "LFCR" prior to market open on November 14, 2022. This new ticker symbol will replace the Company's current ticker symbol "LNDC," which has been used since its initial public offering in 1996. The new corporate name and ticker symbol align with the Company's ongoing strategic transformation toward its high-growth, high-value CDMO business that is focused on the development, fill and f

    11/1/22 8:00:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Schechter Joshua converted options into 9,554 shares, increasing direct ownership by 20% to 57,667 units (SEC Form 4)

    4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

    2/2/24 7:02:00 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Calloway Nathaniel converted options into 3,981 shares, increasing direct ownership by 17% to 28,069 units (SEC Form 4)

    4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

    2/2/24 6:41:59 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Obus Nelson converted options into 9,554 shares, increasing direct ownership by 12% to 88,687 units (SEC Form 4)

    4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

    2/2/24 6:40:32 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Leadership Updates

    Live Leadership Updates

    View All

    Custom Made Meals Appoints Molly Montgomery as Chief Executive Officer

    Custom Made Meals (CMM), a leading national provider of fresh, ready-to-cook (RTC) entrees, appetizers, and sides for the meat and deli departments of retail grocery and club stores, announced today that it has appointed Molly Montgomery as CEO, effective today. Ms. Montgomery has served on the CMM Board of Directors since it was acquired by Stellex Capital Management LLC (Stellex) in May of 2021 and will continue to serve on the board in her new role. Stellex is a middle-market private investment firm with strong experience in the food industry. Ms. Montgomery succeeds Dale Easdon, who has led the Company as CEO for the past three years and has worked closely with management to ensure a sm

    5/17/22 8:30:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Financials

    Live finance-specific insights

    View All

    Landec Corporation Reports First Quarter Fiscal Year 2023 Results

    Lifecore segment revenues increased 8.0% to $23.7 million in fiscal 2023 first quarter versus the prior year periodLifecore segment EBITDA increased 8.1% to $2.5 million in fiscal 2023 first quarter versus the prior year periodReiterates fiscal 2023 full year guidance for LifecoreCorporate rebranding to Lifecore Biomedical continues to progress SANTA MARIA, Calif. and MINNEAPOLIS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. ("Lifecore") and Curation Foods, Inc. ("Curation Foods"), reported results for the fiscal 2023 first

    10/6/22 7:15:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Landec Corporation Revises First Quarter 2023 Earnings Conference Call for October 6, 2022 at 8:00 a.m. ET

    SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced a change to its previously announced fiscal 2023 first quarter earnings conference call date in recognition of Yom Kippur. The Company will now report financial results before the market opens on T

    9/28/22 4:05:00 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Landec Corporation Sets First Quarter 2023 Earnings Conference Call for October 5, 2022 at 2:00 p.m. PT

    SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced that it will host a conference call to discuss fiscal 2023 first quarter financial results. The live webcast can be accessed via Landec's website on the Investor Events & Presentations page. The web

    9/21/22 8:00:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Landec Corporation (Amendment)

    SC 13G/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

    2/9/24 9:59:14 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Landec Corporation (Amendment)

    SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

    1/4/24 4:00:21 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Landec Corporation (Amendment)

    SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

    8/15/23 5:07:46 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care